Diltiazem hydrochloride is a calcium channel blocker widely employed not only in the treatment of cardiovascular disorders like hypertension, angina pectoris & arrythymias but also for the management of migrain, Raynands phenomenon & oesophageal motility disorders. Its water solubility, short elimination half life & therapeutic use in chronic disease, make it suitable as a candidate for prolongation of release from dosage forms. Matrix formulation was prepared to retard the release of drug. Eudragit RS 100,Eudragit RL 100 & Eudragit L were used to prepare matrix tablets. It was found that Eudragit RS 100,Eudragit L & Eudragit RL PM in the ratio of 60:20:20 ; along with plastizers diethyl phthalate (added as 10%dry polymer weight) provided sustained release of drag for period of 12 hours.
展开▼
